cancer
genet
diseas
genet
variat
caus
abnorm
function
gene
appear
alter
express
protein
final
product
gene
express
determin
phenotyp
biolog
process
therefor
detect
gene
express
level
use
cancer
diagnosi
prognosi
treatment
predict
clinic
set
review
investig
six
gene
express
assay
system
qrtpcr
dna
microarray
ncounter
rnaseq
fish
tissu
microarray
current
use
clinic
cancer
studi
method
also
commonli
use
modifi
way
exampl
detect
dna
content
protein
express
herein
discuss
principl
sampl
prepar
design
quantif
sensit
data
analysi
time
sampl
prepar
process
cost
also
compar
method
accord
sampl
select
particularli
feasibl
use
formalinfix
paraffinembed
ffpe
sampl
routin
archiv
clinic
cancer
studi
intend
provid
guidelin
choos
assay
method
respect
oncolog
applic
clinic
set
gener
accept
driver
gene
mutat
initi
cancer
develop
protooncogen
ra
transcrib
product
receptor
growth
factor
transcript
factor
signal
enzym
cellular
prolifer
gainoffunct
mutat
protooncogen
result
domin
oncogen
differ
protooncogen
overexpress
occur
point
mutat
local
redupl
chromosom
transloc
oncogen
therefor
disrupt
cell
normal
activ
lead
uncontrol
cell
divis
ultim
cancer
cell
gene
inhibit
cell
growth
term
tumorsuppressor
gene
includ
apc
loss
underexpress
gene
also
result
uncontrol
cell
divis
therefor
analyz
gene
express
level
biolog
pathway
associ
gene
involv
cancer
one
studi
differ
normal
cell
cancer
cell
pathway
determin
genet
origin
faulti
pathway
therebi
identifi
potenti
target
treat
cancer
potenti
subtyp
cancer
identifi
class
discoveri
identif
novel
cancer
subtyp
class
predict
assign
tumor
sampl
predefin
class
order
aid
predict
outcom
gene
express
analysi
also
allow
biomark
gene
signatur
discoveri
use
gene
express
profil
develop
gene
biomark
signatur
cancer
allow
diagnosi
progress
aggress
analys
prognosi
predict
therapeut
treatment
andor
ivyspr
intern
publish
identif
patient
would
benefit
therapeut
treatment
better
understand
diseas
biolog
variou
assay
technolog
develop
gene
express
analysi
fig
exampl
qrtpcr
amplifi
gene
interest
use
fluoresc
probe
dye
depict
gene
express
nanostr
ncounter
use
probe
pair
anneal
region
rna
detect
gene
dna
microarray
allow
cdna
target
hybrid
probe
solid
slide
use
fluoresc
detect
gene
illumina
miseq
rnaseq
bridg
amplifi
nucleic
acid
sampl
creat
cluster
interpret
miseq
system
lastli
tissu
microarray
tma
studi
circular
punch
tissu
sampl
block
label
probe
antibodi
determin
gene
express
assay
use
diagnosi
prognosi
treatment
predict
varieti
cancer
assay
commerci
clinic
cancer
use
exampl
microarray
test
thyroid
cancer
diagnosi
oncotyp
dx
qrtpcr
test
guid
breast
cancer
treatment
mani
assay
investig
clinic
trial
studi
howev
numer
challeng
involv
tumor
sampl
collect
experiment
design
determin
proper
assay
use
analyt
diagnost
factor
interpret
sampl
biomark
perform
analysi
assay
detect
limit
specif
drug
develop
rare
cancer
clinic
distribut
signific
biomark
must
overcom
develop
novel
clinic
assay
cancer
patient
biomark
develop
also
natur
affect
patient
natur
biolog
histori
intratumor
heterogen
cancer
progress
germlin
mutat
result
prolong
period
biomark
discoveri
patent
clinic
translat
stage
therefor
intend
provid
guidelin
choos
assay
method
respect
oncolog
applic
clinic
set
principl
pcr
polymeras
chain
reaction
first
invent
kari
mulli
colleagu
cetu
corpor
exploit
abil
taq
polymeras
thermu
aquaticu
amplifi
dna
withstand
elev
temperatur
revers
transcript
pcr
rtpcr
rna
first
revers
transcrib
cdna
amplifi
first
gener
rtpcr
use
band
intens
gel
semiquantif
realtim
quantit
revers
transcript
pcr
realtim
qrtpcr
digit
pcr
develop
instead
detect
much
pcr
product
gener
convent
pcr
qrtpcr
count
mani
reaction
cycl
use
reach
amplif
slope
statu
realtim
ct
cycl
threshold
level
defin
number
cycl
requir
fluoresc
signal
cross
threshold
ie
exce
background
level
invers
proport
amount
target
nucleic
acid
sampl
ie
lower
ct
level
greater
amount
target
nucleic
acid
sampl
first
step
requir
revers
transcript
mrna
templat
primer
pair
anneal
target
cdna
templat
dna
polymeras
eg
taq
extend
ligat
primer
thermal
cycler
vari
temperatur
set
perform
three
stage
pcr
denatur
anneal
extens
final
standard
dissoci
curv
studi
determin
initi
amount
rna
cdna
transcript
primer
design
primer
requir
qrtpcr
analysi
anneal
specif
portion
mrna
dna
polymeras
extend
primer
amplifi
gene
interest
factor
consid
primer
design
melt
temperatur
gc
content
forward
revers
primer
rang
report
consid
stringent
tight
anneal
primer
mrna
templat
reduc
chanc
primerdim
hairpin
lastli
primer
span
exonexon
junction
allow
strict
amplif
mrna
sampl
contamin
dna
dna
contain
altern
region
exon
intron
mrna
lack
intron
freewar
help
primerprob
design
exampl
primer
design
tool
ncbi
mani
commerci
compani
provid
qrtpcr
taq
polymeras
enzym
mixtur
reaction
solut
besid
digit
pcr
detect
actual
copi
mrna
altern
pcr
method
two
major
qrtpcr
system
taqman
sybr
green
taqman
qrtpcr
specif
probe
label
fluoresc
report
bound
cdna
target
rna
taq
polymeras
enzym
degrad
probe
chain
extens
fluoresc
report
releas
amount
pcr
product
quantit
measur
fluoresc
report
detect
differ
report
dye
util
taqman
assay
sensit
taqman
assay
one
major
advantag
also
high
specif
specif
probe
use
multiplex
gene
target
sybr
green
qrtpcr
fluoresc
dye
sybr
green
bind
amplifi
doubl
strand
dna
emit
intens
green
light
therefor
pcr
product
measur
detect
bound
sybr
green
fluoresc
compar
taqman
qrtpcr
method
inexpens
easi
use
use
multiplex
gene
target
howev
due
abil
bind
doublestrand
dna
nonspecif
bind
lead
quantif
pcr
product
data
analysi
quantit
result
gener
requir
studi
output
dissoci
curv
allow
graph
known
rna
concentr
use
refer
curv
construct
unknown
rna
quantiti
approach
known
standard
curv
method
compar
ct
method
involv
compar
ct
valu
interest
control
nontreat
normal
sampl
normal
housekeep
gene
biostatist
analysi
also
done
final
gene
express
valu
logtransform
normal
symmetr
data
distribut
commerci
rtpcr
assay
develop
interpac
diagnost
inc
use
diagnosi
thyroid
nodul
one
common
cancer
type
base
evalu
express
mirna
wellknown
oncotyp
dx
gene
express
profil
techniqu
develop
genom
health
first
genom
biomark
assay
advis
breast
cancer
treatment
option
identif
candid
gene
known
function
relev
hormon
receptorposit
breast
cancer
signatur
refer
gene
cancerrel
gene
involv
tumor
prolifer
invas
estrogen
signal
establish
abl
predict
recurr
risk
earlystag
stage
ii
estrogen
receptor
er
posit
lymph
node
neg
breast
cancer
patient
assess
predict
efficaci
adjuv
chemotherapi
act
treat
patient
techniqu
similar
oncotyp
dx
also
appli
colon
cancer
exampl
two
separ
studi
establish
signatur
cancerrel
gene
refer
gene
studi
stage
ii
colon
cancer
qrtpcr
also
appli
monitor
develop
sever
acut
respiratori
syndrom
sar
associ
coronaviru
detect
prognost
marker
leukemia
studi
establish
gene
signatur
human
prostat
cancer
rna
extract
snapfrozen
human
prostat
surgic
tissu
sampl
revers
transcrib
use
random
hexam
superscript
ii
revers
transcriptas
qrtpcr
aid
identif
gene
interest
ornithin
decarboxylas
ornithin
decarboxylas
antizym
adenosylmethionin
decarboxylas
spermidinespermin
n
acetyltransferas
histon
growth
arrest
specif
gene
glyceraldehyd
dehydrogenas
clusterin
qrtpcr
also
success
appli
nonsmal
cell
lung
cancer
nsclc
studi
establish
signatur
cancerrel
target
gene
refer
gene
identifi
gene
essenti
treatment
outcom
predict
develop
dna
microarray
trace
late
earli
method
fluoresc
detect
adapt
progress
array
technolog
dna
microarray
use
quantif
either
genom
dna
rna
two
type
dna
microarray
array
array
array
slide
made
spot
cdna
fragment
custom
cdna
array
oligonucleotid
probe
agil
treat
sampl
cdna
normal
control
sampl
cdna
label
two
type
fluoresc
exampl
cdna
tumor
sampl
may
label
cdna
normal
tissu
sampl
may
label
mixtur
treat
control
sampl
hybrid
array
ratio
intens
spot
repres
gene
express
treat
sampl
rel
control
agil
produc
commerci
array
array
oligonucleotid
probe
synthes
surfac
slide
fluoresc
label
sampl
cdna
hybrid
array
absolut
intens
hybrid
signal
measur
affymetrix
genechip
typic
array
illumina
beadarray
variat
array
synthes
barcod
probe
surfac
microbead
make
cell
fill
bead
dna
microarray
assay
need
commerci
array
custom
design
array
cdna
label
prepar
rna
sampl
follow
hybrid
cdna
sampl
array
scan
devic
imag
measur
fluoresc
level
microarray
three
main
manufactur
commerci
microarray
affymetrix
genechip
illumina
beadarray
agil
array
microarray
meet
kind
need
human
gene
express
detect
whole
genomewid
transcriptom
detect
special
panel
gene
express
detect
need
custom
array
design
commerci
compani
normal
requir
remov
variat
experi
affect
gene
express
level
necessari
earlier
stage
microarray
examin
follow
analys
affect
normal
follow
imag
microarray
raw
data
first
analyz
subtract
background
fluoresc
fluoresc
spot
select
appropri
housekeep
gene
gene
delic
task
gene
previous
thought
ideal
refer
shown
vari
express
level
depend
circumst
donor
biolog
state
common
normal
method
nonlinear
local
weight
scatterplot
smooth
lowess
method
appli
backgroundadjust
intens
microarray
assay
develop
veracyt
corpor
south
san
francisco
california
gene
express
classifi
measur
express
gene
transcript
classifi
aspir
materi
thyroid
nodul
either
benign
suspici
mammaprint
signatur
deriv
express
gene
use
dna
microarray
assay
predict
distant
diseasefre
surviv
overal
surviv
lymphnod
neg
patient
also
shown
signific
prognost
result
lymphnod
posit
tumor
costeffect
shown
improv
qualityadjust
surviv
identifi
patient
lowrisk
group
chanc
diseasefre
minimum
year
allow
refrain
unnecessari
adjuv
chemotherapi
dna
microarray
use
determin
differ
subtyp
lung
squamou
cell
carcinoma
scc
stratifi
patient
accur
prognos
target
research
one
studi
use
scc
patient
five
publish
cohort
dna
microarray
detect
subtyp
collect
assay
scc
patient
valid
four
independ
subtyp
identifi
statist
bioinformat
use
determin
subtyp
surviv
outcom
clinic
covari
biolog
process
dna
microarray
also
employ
evalu
express
purifi
leukem
cell
chronic
lymphocyt
leukemia
cll
patient
determin
express
level
high
tcell
use
identifi
patient
requir
certain
treatment
assign
patient
cll
correct
igvh
mutat
subtyp
high
correl
concord
shown
spread
mrna
level
dna
microarray
qrtpcr
assay
dasl
tm
cdnamedi
anneal
select
extens
ligat
assay
target
genespecif
sequenc
establish
use
ffpe
sampl
prostat
lung
colon
breast
tissu
type
ncounter
technolog
robust
sensit
reproduc
easytous
method
develop
nanostr
technolog
ncounter
variat
dna
microarray
employ
two
base
probe
per
mrna
hybrid
solut
report
probe
carri
signal
captur
probe
allow
complex
immobil
digit
analyz
detect
colour
code
digit
analyz
sens
hybrid
colourcod
probe
captur
signal
intens
gene
express
mrna
level
probe
anneal
directli
rna
sampl
revers
transcript
produc
cdna
requir
assay
wide
rang
potenti
applic
diagnost
valid
gene
express
experi
diseas
eg
cancer
research
gene
regulatori
pathway
ultim
lead
translat
data
clinic
use
probe
design
probe
pair
construct
uniqu
gene
probe
pair
compris
captur
report
probe
base
long
complementari
individu
rna
molecul
captur
probe
attach
via
end
affin
tag
biotin
report
probe
detect
coupl
via
end
colourcod
tag
backbon
singlestrand
dna
ligat
rna
molecul
label
fluorophor
four
differ
colour
fluorophor
six
avail
posit
colour
code
confer
wide
rang
tag
mix
singlewel
reaction
success
resolv
identifi
data
analysi
enzymekit
probe
attach
directli
rna
sampl
detect
enzym
requir
captur
report
probe
mix
rna
solut
prior
form
tripartit
structur
via
hybrid
design
segment
two
kit
reagent
requir
codeset
master
kit
codeset
custom
predesign
probe
depend
one
experiment
protocol
set
system
control
master
kit
contain
readytoload
consum
reagent
assay
digit
analyz
identifi
scan
count
molecular
barcod
per
sampl
data
analysi
digit
analyz
use
ccd
camera
microscop
object
len
magnifi
imag
immobil
report
captur
hundr
imag
per
sampl
output
hundr
thousand
count
process
imag
export
data
comma
separ
csv
output
file
use
input
nsolver
tm
analysi
softwar
nsolver
tm
softwar
perform
qualiti
control
qc
data
normal
analysi
normal
need
account
variat
hybrid
purif
bind
effici
experiment
factor
nanostr
recommend
appli
intern
posit
control
codeset
remov
variabl
addit
posit
control
refer
housekeep
gene
normal
global
plex
normal
may
also
perform
cancer
clinic
prosigna
wellknown
nanostr
ncounter
assay
measur
risk
relaps
ror
prognost
factor
relapsefre
surviv
breast
cancer
patient
nodeneg
tumor
receiv
adjuv
system
therapi
one
studi
use
custom
design
ncounter
codeset
gene
element
studi
colon
cancer
discov
subset
gene
serv
potenti
biomark
cancer
prognosi
ffpe
tissu
sampl
moder
correl
ncounter
microarray
platform
assay
includ
multipl
publish
gene
signatur
colon
cancer
prognosi
sever
candid
gene
element
ongo
studi
intestin
stem
cell
biolog
epithelialtomesenchym
transit
emt
anoth
studi
nanostr
ncounter
technolog
chosen
assay
rna
extract
ffpe
sampl
stage
ii
gastric
cancer
patient
base
abil
evalu
express
level
gene
screen
patient
identif
prognost
gene
evalu
strength
prognost
algorithm
gene
identifi
togeth
effici
predict
patient
outcom
recurr
cancer
postsurgeri
regardless
prior
adjuv
chemotherapi
hope
prognost
signatur
valid
phase
iii
trial
extract
analysi
ng
rna
freshfrozen
tissu
ffpe
sampl
signatur
medulloblastoma
patient
establish
use
specif
nanostr
ncounter
codeset
demonstr
high
concord
ncounter
assay
affymetrix
express
array
data
use
medulloblastoma
sampl
second
group
nonoverlap
medulloblastoma
known
subgroup
three
laboratori
canada
switzerland
unit
state
demonstr
reproduc
assay
principl
rna
sequenc
rnaseq
directli
sequenc
count
mrna
molecul
whole
transcriptom
select
measur
gene
express
detect
genom
chang
diseas
state
four
step
involv
rnaseq
mrna
transcript
fragment
primer
allow
randomli
anneal
mrna
segment
first
second
strand
cdna
synthesi
revers
transcript
mrna
fragment
result
doublestrand
cdna
end
fragment
tag
phosphat
group
poli
tail
final
adaptor
ligat
onto
cdna
fragment
pcr
amplif
sequenc
perform
sequenc
involv
continu
addit
fluoresc
label
nucleotid
base
four
colour
adaptor
sequenc
follow
photo
imag
machin
time
base
ad
imag
translat
sequenc
base
benchtop
applianc
sequenc
cdna
templat
gener
sequenc
read
densiti
million
individu
molecular
cluster
per
squar
centimet
cluster
gener
sequenc
synthesi
sb
data
analysi
kitrna
librari
prepar
miseq
rna
prepar
kit
illumina
truseq
rnaseq
kit
purchas
manufactur
kit
includ
revers
transcriptas
revers
transcript
rna
cdna
primer
adaptor
sampl
prepar
result
ligat
adaptor
end
nucleic
acid
fragment
data
analysi
miseq
conduct
basic
data
analysi
miseq
control
softwar
mc
sequenc
analysi
viewer
sav
instal
anoth
comput
miseq
report
gener
fastqformat
file
contain
sequenc
read
sampl
qualiti
score
miseq
analysi
folder
contain
basecal
folder
fastq
file
sent
target
rna
workflow
output
bam
file
contain
refer
genom
variou
annot
set
chromosom
size
target
hit
file
align
replic
count
per
transcript
fastq
file
export
miseq
analys
altern
read
align
pose
complic
rnaseq
read
compar
refer
genom
exonexon
splice
junction
exist
rna
transcript
dna
transcript
rnaseq
align
tool
correct
includ
gsnap
mapsplic
rum
star
tophat
mapsplic
exampl
search
exonsplic
junction
sampl
mrna
transcriptom
determin
like
align
mrna
tag
refer
genom
first
phase
tag
align
phase
potenti
align
mrna
tag
refer
genom
identifi
second
phase
splice
interfer
phase
splice
junction
appear
one
tag
studi
qualiti
divers
align
output
splice
signific
score
follow
read
align
transcript
form
map
read
use
comput
softwar
program
cufflink
fluxcapacit
count
total
number
read
map
transcript
quantifi
gene
express
data
sampl
normal
read
per
kilobas
per
million
librari
read
rpkm
normal
express
level
per
replic
perform
base
number
align
read
varianc
estim
requir
divid
raw
varianc
sampl
id
squar
mean
deriv
pvalu
differenti
express
per
transcript
requir
neg
binomi
distribut
model
normal
transcript
abund
benjaminihochberg
procedur
use
calcul
qvalu
correct
multipl
hypothesi
test
fals
discoveri
rate
fdr
statist
result
summar
output
align
folder
sever
studi
use
nextgener
sequenc
ng
technolog
cancer
gene
analysi
andor
signatur
develop
exampl
one
studi
use
ng
analyz
includ
tumor
suppressor
gene
associ
breast
ovarian
cancer
ng
also
use
determin
instabl
examin
pathogen
properti
clinic
impact
result
larg
number
somat
microdelet
exon
affect
epiderm
growth
factor
receptor
egfr
nsclc
select
patient
leukemia
design
amplicon
target
cebpa
cbl
nra
kra
one
studi
analyz
robust
pcr
amplif
strategi
gs
flx
titanium
illumina
miseq
amplicondeep
sequenc
platform
aim
evalu
technolog
routin
clinic
use
character
monitor
diseas
use
individu
patient
assay
miseq
could
detect
variant
pair
insertiondelet
confer
predict
characterist
assay
detect
residu
diseas
identifi
mutat
assign
treatment
miseq
rnaseq
techniqu
also
use
assess
purpos
tumoreduc
blood
platelet
tep
system
local
respons
tumor
growth
use
total
platelet
sampl
patient
local
metastas
tumor
nondiseas
individu
mutat
kra
egfr
plasma
dna
platelet
rna
detect
bloodbas
oncosignatur
deriv
tep
mrna
profil
examin
tissu
biomark
stratif
patient
lowand
highrisk
group
select
therapi
although
clinic
relev
blood
platelet
molecular
diagnosi
patient
present
sever
type
cancer
establish
system
factor
chronic
diseas
transient
diseas
state
andor
noncancer
diseas
could
affect
tep
mrna
profil
prompt
valid
bloodbas
therapi
select
longitudin
studi
diseas
recurr
monitor
principl
fish
develop
earli
appli
fluorescentlabel
short
dna
probe
hybrid
target
dna
rna
sequenc
situ
fluoresc
microscopi
local
detect
target
tissu
slide
fish
determin
presenc
absenc
mrna
express
gene
interest
well
local
gene
express
specif
cell
pretreat
requir
preserv
rna
tissu
morpholog
cell
ffpe
frozen
tissu
section
fix
permeabil
allow
target
access
targetspecif
probe
hybrid
target
rna
separ
compat
signal
amplif
system
enabl
multiplex
assay
signal
amplif
achiev
via
seri
sequenti
hybrid
step
multicolor
fish
use
identifi
mani
label
featur
differ
fluorophor
use
hybrid
probe
design
mani
differ
type
probe
use
fish
includ
cdna
crna
synthet
oligonucleotid
probe
probe
size
import
longer
probe
hybrid
specif
shorter
probe
strand
dna
rna
often
nucleotid
complementari
given
target
sequenc
often
use
locat
target
data
analysi
autom
fluoresc
signal
analysi
system
analyz
fluoresc
signal
pattern
fish
spot
cell
cell
nuclei
automat
precis
reproduc
signal
channel
combin
assay
imag
obtain
channel
process
individu
morpholog
target
cell
nuclei
object
precis
defin
number
cell
select
paramet
multipl
featur
object
eg
area
shape
intens
signal
distribut
measur
applic
fish
grow
rapidli
genom
cytogenet
prenat
research
tumor
biolog
radiat
label
gene
map
gene
amplif
basic
biomed
research
well
clinic
applic
diagnost
purpos
gene
express
assay
fish
use
local
detect
specif
rna
target
mrna
lncrna
mirna
tumor
cell
tissu
one
studi
fish
use
assess
transcript
distribut
fresh
frozen
human
breast
cancer
tissu
section
kra
wildtyp
mutant
cell
padlock
probe
oligonucleotid
circular
follow
hybrid
target
sequenc
complementari
probe
end
design
detect
cdna
molecul
roll
circl
amplif
use
amplifi
circular
padlock
probe
express
vari
expect
somat
point
mutat
identifi
kra
small
molecul
inhibitor
antibodi
target
met
protooncogen
ligand
hepatocyt
growth
factor
hgf
develop
test
clinic
trial
one
studi
analyz
met
express
activ
match
set
ffpe
vs
fresh
frozen
tumor
sampl
consist
case
gastric
cancer
use
fish
ihc
found
rna
fish
use
confirm
find
obtain
ihc
potenti
may
replac
ihc
certain
target
suitabl
antibodi
avail
rna
fish
valid
platform
test
predict
biomark
patient
select
microrna
mirna
excel
tumor
biomark
celltyp
specif
abund
reliabl
multicolor
mirna
fish
techniqu
develop
enabl
mirna
visual
ffpe
tissu
test
two
skin
tumor
basal
cell
carcinoma
bcc
merkel
cell
carcinoma
mcc
visual
differenti
express
mirna
ffpe
tumor
sampl
qrtpcr
analysi
fish
appli
studi
assess
mirna
express
breast
cancer
cell
found
express
significantli
lower
level
tumor
tissu
compar
adjac
normal
tissu
directli
target
fish
also
use
lncrna
express
detect
cancer
exampl
one
studi
use
rna
fish
investig
associ
lncrna
express
clinicopatholog
characterist
prognosi
gastric
cancer
patient
separ
studi
demonstr
two
antisens
lncrna
end
human
gene
kidney
tumor
tissu
use
rna
fish
principl
develop
kononen
associ
tissu
microarray
tma
requir
combin
small
tissu
sampl
sausag
block
studi
connect
tissu
sampl
slide
clinic
data
use
situ
analys
fluoresc
situ
hybrid
fish
rna
situ
hybrid
ish
immunohistochemistri
techniqu
tma
detect
protein
stain
cellular
locat
offer
applic
molecular
diagnost
studi
howev
number
protein
detect
limit
antibodi
tma
expand
gene
express
serial
analysi
cdna
microarray
requir
singl
experi
studi
gene
express
mani
gene
singl
tumor
sampl
allow
multipl
patient
sampl
repres
variou
stage
diseas
simultan
investig
use
tma
slide
probe
hybrid
signal
detect
instrument
scanner
data
follow
data
analysi
tma
offer
advantag
permit
singl
set
tissu
associ
clinic
data
use
variou
unlimit
studi
step
gener
requir
prepar
tma
follow
prepar
highadhes
glass
slide
acquisit
donor
tissu
tissu
core
map
arrang
sampl
section
transfer
tissu
donor
core
tissu
stain
molecular
analysi
first
sampl
taken
ffpe
tissu
map
tissu
section
stain
hematoxylin
eosin
h
e
tissu
array
remov
core
donor
block
place
recipi
block
primerprob
design
fish
requir
dna
probe
typic
clone
sourc
eg
plasmid
target
dna
form
chromosom
interphas
chromatin
bind
probe
dna
probe
label
hapten
fluorochrom
dyebas
nucleotid
dna
probe
target
dna
permit
hybrid
follow
denatur
singl
strand
fluoresc
microscopi
allow
visual
dna
probetarget
dna
complex
similar
fish
rna
ish
requir
genespecif
nucleotid
probe
bind
certain
sequenc
dna
rna
strand
probe
may
label
radio
antigen
fluorescentlabel
base
analyz
autoradiographi
immunohistochemistri
fluoresc
microscopi
respect
minut
tissu
sampl
typic
mm
diamet
differ
tissu
analyz
one
microscop
glass
slide
sinc
tissu
sampl
simultan
analyz
set
reagent
standard
speed
process
cost
effici
normal
account
technic
experiment
varianc
sampl
need
extens
perform
tissu
section
first
analyz
via
h
e
stain
immunofluoresc
ish
autom
scan
system
purchas
scan
analyz
prepar
tma
slide
test
carri
tma
may
vari
depend
one
experiment
design
purpos
differ
combin
gene
detect
analysi
may
perform
autoradiographi
immunohistochemistri
may
appli
detect
follow
fluoresc
microscopi
imag
array
scanner
may
use
assess
fluoresc
level
tma
exampl
one
use
digit
imag
scan
process
technolog
microsoft
access
excel
databas
compar
result
clinic
data
variou
techniqu
exist
visual
tma
numer
data
analysi
normal
method
develop
tissu
array
manag
evalu
environ
tame
webbas
databas
applic
store
experiment
paramet
tma
imag
evalu
result
avail
tma
data
analysi
manag
whole
tma
workflow
tissu
array
cooccurr
matrix
analysi
tacoma
use
local
interpixel
relationship
quantifi
cellular
phenotyp
recogn
specif
stain
pattern
output
score
categor
studi
candid
gene
rna
dna
andor
protein
molecular
alter
sampl
tma
use
research
diseas
cancer
drug
target
discoveri
determin
therapeut
import
gene
patient
well
diagnost
prognost
signific
cancer
allow
examin
tumor
progress
identif
valid
prognost
factor
gene
potenti
translat
clinic
set
therapeut
treatment
exampl
tma
use
origin
experi
studi
amplif
six
gene
well
express
estrogen
receptor
er
breast
cancer
allow
stratif
cancer
subgroup
examin
molecular
chang
bladder
cancer
patient
affect
clinic
outcom
tissu
microarray
construct
use
sampl
patient
studi
outcom
amplif
ccne
protein
express
four
independ
tma
use
analyz
prognost
marker
er
pr
impact
molecular
chang
clinic
endpoint
breast
carcinoma
mm
sampl
taken
one
central
three
peripher
region
ffpe
sampl
multipl
punch
per
tumor
taken
demonstr
tumor
could
distinguish
three
subgroup
posit
neg
heterogen
tma
construct
use
three
antibodi
four
array
demonstr
signific
associ
tumorspecif
surviv
larg
section
analys
singl
sampl
per
tumor
suffici
identifi
associ
molecular
alter
clinic
outcom
valid
establish
molecular
marker
requir
use
larger
tissu
sampl
clinic
trial
mani
previou
studi
assess
er
express
use
immunohistochemistri
reproduc
one
studi
use
tma
examin
variabl
er
express
report
breast
cancer
independ
laboratori
construct
tma
core
invas
breast
cancer
donor
block
patient
twice
moder
high
interlaboratori
agreement
determin
demonstr
tma
effici
identif
er
variabl
report
potenti
appli
similar
project
tma
clinic
sampl
vari
stage
prostat
cancer
use
studi
express
candid
gene
discov
cdna
microarray
xenograft
model
use
prostat
intraepitheli
neoplasia
primari
tumor
distal
metastas
hormon
refractori
specimen
sampl
benign
prostat
hyperplasia
act
control
demonstr
use
crym
affect
androgenindepend
growth
therapi
failur
prostat
cancer
follow
mrna
situ
hybrid
immunohistochem
analys
tma
strong
correl
found
cdna
microarray
mrna
overexpress
hormonerefractori
xenograft
seen
crym
downregul
anoth
studi
use
tma
sampl
prostat
tissu
examin
signific
polycomb
group
protein
progress
prostat
cancer
includ
cohort
sampl
individu
pass
away
hormon
refractori
metastat
prostat
cancer
highli
express
mainli
seen
nucleu
stain
increas
across
benign
prostat
atrophi
prostat
intraepitheli
neoplasia
clinic
local
prostat
cancer
subgroup
metastat
prostat
cancer
demonstr
highest
intens
stain
group
also
analyz
valid
tissu
biomark
prostat
cancer
consid
clinic
patholog
factor
use
tma
patient
provid
clinic
followup
demonstr
potenti
biomark
prostat
cancer
concentr
affect
diseas
aggress
abnorm
express
may
progress
cancer
compar
qrtpcr
dna
microarray
nanostr
ncounter
illumina
miseq
rnaseq
fish
tissu
microarray
assay
primerprob
design
sampl
prepar
instrument
use
data
analysi
reproduc
specif
sensit
throughput
complex
process
data
analysi
use
research
commerci
tabl
cost
time
use
tabl
cell
lysat
fresh
frozen
ff
tissu
ffpe
sampl
wide
use
cancer
genom
studi
qrtpcr
dna
microarray
nanostr
ncounter
illumina
miseq
rnaseq
assay
provid
data
patient
diagnosi
prognosi
fish
tma
also
employ
ffpe
specimen
ff
sampl
allow
better
preserv
rna
limit
avail
use
tissu
bank
research
group
mainli
collect
studi
also
disadvantag
sampl
size
transport
clinic
annot
rna
isol
purif
step
gener
qrtpcr
dna
microarray
nanostr
ncounter
illumina
miseq
rnaseq
method
commerci
kit
may
purchas
rna
extract
cell
lysat
ffpe
ff
sampl
tma
longer
process
sampl
prepar
use
ffpe
sampl
purpos
formalin
fixat
paraffin
embed
ffpe
protocol
preserv
protein
test
fish
immunohistochemistri
rather
nucleic
acid
strand
tma
requir
rna
extract
appli
fluoresc
detect
test
fish
ish
make
use
longterm
storag
abund
sampl
acquir
ffpe
sampl
although
ff
sampl
provid
better
qualiti
sampl
microarray
analys
microarray
oligonucleotid
probe
consist
detect
ffpe
ff
specimen
ffpe
sampl
also
commonli
use
microarray
gene
express
analys
due
differ
tissu
characterist
ffpe
ff
sampl
yield
cdna
revers
transcript
amplif
ffpe
ff
sampl
may
vari
match
ff
ffpe
sampl
studi
evalu
integr
consist
gene
express
ffpe
sampl
shown
ffpe
sampl
may
use
gene
express
analysi
similarli
ff
sampl
prefer
rnaseq
experi
provid
better
qualiti
data
studi
shown
ffpeff
pair
demonstr
high
correl
analyz
gene
express
storag
time
specimen
less
two
year
mean
reliabl
rna
extract
ffpe
sampl
younger
tissu
block
sinc
requir
captur
report
probe
anneal
templat
report
probe
depict
gene
interest
sampl
prevent
accumul
error
revers
transcript
step
allow
ffpe
sampl
util
nanostr
ncounter
shown
ncounter
experi
high
concord
rate
immunohistochemistri
demonstr
reproduc
although
ncounter
show
promis
use
ffpe
sampl
limit
detect
gene
limit
present
matter
sampl
type
chosen
due
sourc
variat
intratumor
heterogen
individu
ffpe
tissu
vari
rna
qualiti
therefor
produc
best
result
ffpe
tissu
standard
method
rna
extract
must
establish
studi
compar
trizol
qiagen
rneasi
ffpe
arcturu
picopur
rna
isol
kit
quantiti
qualiti
rna
microarray
gene
express
studi
effici
method
rna
extract
deparaffin
microarray
hybrid
step
develop
protocol
includ
rneasi
ffpe
kit
modifi
deparaffin
protocol
rna
isol
ffpe
tissu
combin
array
ovat
ffpe
wta
system
kit
amplif
hybrid
workflow
improv
ffpe
tissu
reliabl
altern
ff
sampl
although
qrtpcr
test
shown
consist
result
across
replic
assay
reproduc
error
may
amplifi
along
exponenti
amplif
origin
nucleotid
strand
pcr
result
loss
inform
amplif
express
microarray
also
shown
highli
reproduc
depend
abil
probe
anneal
number
transcript
across
replic
experi
protocol
use
rna
extract
sampl
purif
data
acquisit
normal
type
construct
probe
method
label
hybrid
use
greatli
affect
reproduc
dna
microarray
numer
studi
confirm
reproduc
nanostr
ncounter
platform
due
requir
littl
input
rna
lack
revers
transcript
step
exampl
reproduc
demonstr
use
diffus
bcell
lymphoma
dlbcl
gastric
pancrea
xenograft
lung
breast
blood
melanoma
sampl
separ
studi
demonstr
interlaboratori
canada
switzerland
unit
state
reproduc
ncounter
medulloblastoma
sampl
similarli
studi
use
techniqu
pcr
qrtpcr
microarray
show
miseq
platform
rnaseq
reproduc
exampl
seqcmaqciii
consortium
demonstr
rnaseq
valid
quantit
pcr
qpcr
sequenc
unannot
exonexon
junction
yet
microarray
provid
reliabl
reproduc
data
one
greatest
drawback
tma
tumor
interheterogeneityth
fact
singl
spot
punch
tumor
block
repres
rest
tumor
regardless
tma
high
degre
reproduc
due
maximum
spot
singl
slide
simultan
sampl
subject
experiment
test
use
reagent
multipl
punch
sampl
one
tumor
block
allow
tumor
block
use
multipl
experi
exampl
tma
one
recipi
block
distribut
lab
immunohistochem
fish
test
standard
reproduc
result
sensit
refer
minimum
amount
substanc
rna
detect
per
sampl
experiment
assay
qrtpcr
pcr
report
sensit
copi
mrna
per
cell
mani
copi
per
cell
detect
pcr
littl
copi
per
cell
detect
pcr
impli
number
could
similar
qrtpcr
similarli
dna
microarray
detect
copi
mrna
per
cell
ncounter
miseq
abil
sens
copi
mrna
per
cell
ncounter
util
regionspecif
colourcod
probe
bind
singl
transcript
wherea
miseq
gener
cluster
copi
singl
transcript
lastli
sensit
tma
analyz
number
way
may
depend
size
tissu
spot
array
sensit
test
eg
fish
ish
use
exampl
tma
array
differ
sampl
spot
singl
array
allow
mm
smallest
sampl
size
taken
effici
detect
result
situ
hybrid
shown
sensit
mrna
copi
per
cell
specif
qrtpcr
dna
microarray
nanostr
ncounter
miseq
rnaseq
tma
depend
primersprob
andor
reagent
use
previous
discuss
strict
design
requir
ensur
qrtpcr
primer
tightli
anneal
mrna
transcript
amplifi
section
interest
therefor
specif
qrtpcr
depend
forward
revers
primer
design
well
oligonucleotid
probe
use
detect
specif
dna
microarray
depend
number
factor
densiti
probe
anneal
slide
singl
probe
hybrid
probe
singl
target
singl
spot
spot
multipl
probe
may
contain
probe
perfectli
partial
hybrid
target
spotset
multipl
spot
repres
differ
section
sequenc
similar
pcr
specif
may
also
depend
probe
design
exampl
cdna
microarray
employ
probe
thousand
base
pair
length
oligonucleotid
array
perform
best
shorter
probe
length
specif
nanostr
ncounter
due
targetspecif
captur
report
probe
design
anneal
nucleic
acid
region
interest
combin
intern
control
use
form
codeset
confer
overal
specif
tma
qualiti
depend
type
analysi
done
exampl
fish
rna
fish
immunohistochemistri
confer
differ
specif
tma
assay
rna
probe
nucleotid
length
common
recommend
nucleotid
tend
demonstr
high
specif
chemicallysynthes
oligonucleotid
label
fluorophor
calibr
certain
region
tend
gener
rna
fish
probe
high
specif
high
throughput
refer
advantag
technolog
simultan
analyz
mani
ie
hundr
thousand
sampl
certain
set
condit
therefor
may
depend
number
gene
detect
techniqu
andor
number
sampl
process
wellplat
hold
maximum
sampl
purchas
pcr
although
control
sampl
test
prime
housekeep
gene
replic
recommend
number
three
run
singl
plate
qrtpcr
assay
potenti
assess
sampl
substanti
number
well
also
allow
analys
hundr
gene
singleplex
reaction
number
sampl
analyz
dna
microarray
depend
purpos
microarray
number
gene
assess
wholegenom
array
perform
individu
small
number
individu
simultan
analyz
certain
set
gene
one
array
exampl
prosigna
abl
assess
breast
cancer
patient
sampl
featur
singl
array
report
differ
probe
avail
detect
microarray
detect
repres
differ
gene
ncounter
capac
input
sampl
detect
gene
approxim
gene
target
sampl
process
use
miseq
benchtop
sequenc
cluster
molecul
amplicon
gener
singl
transcript
anywher
thousand
target
report
similar
dna
microarray
number
sampl
assess
gene
detect
tma
depend
purpos
gener
spot
repres
differ
sampl
array
tma
although
mani
gene
abil
detect
differ
colour
probe
design
anneal
target
region
studi
tend
depict
gene
use
fluoresc
detect
tma
may
resolut
difficult
use
mani
differ
probe
situ
detect
assay
qrtpcr
reaction
per
sampl
consid
cheap
cost
variou
kit
obtain
accord
one
experiment
design
revers
transcrib
mrna
cdna
carri
remaind
qrtpcr
step
accord
biosearch
technolog
reagent
cost
account
singl
qrtpcr
reaction
total
probe
use
detect
method
total
cost
per
reaction
sybr
use
total
cost
per
reaction
increas
qrtpcr
dna
microarray
nanostr
ncounter
illumina
miseq
requir
isol
purif
rna
follow
rna
extract
qrtpcr
requir
mix
variou
reagent
allow
sampl
revers
transcrib
wellplat
must
care
prepar
prior
subject
sampl
pcr
dissoci
curv
analysi
step
thermal
cycler
machin
comput
respect
take
hour
includ
rna
extract
step
similarli
dna
microarray
requir
revers
transcript
step
rna
extract
time
requir
allow
sampl
hybrid
array
array
preorder
construct
laboratori
microarray
scanner
analyz
slide
comput
softwar
purchas
data
analysi
result
total
time
hour
nanostr
ncounter
requir
user
prepar
initi
sampl
transfer
sampl
prep
station
digit
analyz
machin
machin
carri
process
data
analysi
need
done
result
total
hour
similar
ncounter
illumina
miseq
requir
user
prepar
librari
load
onto
reagent
cartridg
rest
sampl
process
data
analysi
carri
miseq
benchtop
sequenc
miseq
report
analysi
softwar
launch
follow
complet
trial
total
hour
requir
tma
construct
tediou
procedur
therefor
requir
work
demand
averag
two
day
depend
exact
procedur
follow
donor
tissu
block
avail
one
must
collect
sampl
prior
prepar
block
slide
tissu
sampl
must
stain
one
use
tissu
array
accur
remov
core
donor
block
place
slide
follow
construct
slide
reagent
fish
ish
immunohistochemistri
test
must
prepar
appli
slide
slide
analyz
eye
digit
slide
scanner
discuss
earlier
five
assay
use
clinicalrel
studi
analyz
gene
express
cancer
patient
sampl
qrtpcr
dna
microarray
nanostr
ncounter
assay
commerci
product
oncotyp
dx
mammaprint
prosigna
respect
test
clinic
sampl
illumina
miseq
assay
yet
one
send
sampl
institut
process
tissu
microarray
also
commerci
assay
use
detect
gene
maximum
sampl
requir
cohort
patient
sampl
gather
construct
tma
therefor
ideal
valid
studi
use
qrtpcr
dna
microarray
et
cetera
assess
individu
small
number
sampl
summar
main
advantag
disadvantag
method
tabl
setup
matrix
tabl
guid
choos
practic
assay
base
gene
number
test
purpos
assay
locat
experi
perform
frequenc
assay
sampl
process
fee
littl
singl
gene
experiment
time
hour
includ
rna
isol
purif
well
pcr
data
analysi
qrtpcr
offer
cheapest
quickest
assay
process
individu
clinic
sampl
gene
small
laboratori
hospit
lab
clinic
lab
suit
clinic
process
environ
purchas
thermal
cycler
littl
process
analyz
sampl
techniqu
employ
machin
cost
better
suit
larger
research
institut
feasibl
clinic
sampl
sent
institut
nation
lab
process
cost
constraint
ncounter
suit
detect
gene
microarray
good
gene
genomewid
gene
express
profil
rnaseq
detect
larg
number
gene
addit
benefit
gene
discoveri
suit
cancer
research
institut
tma
appropri
protein
level
detect
thousand
sampl
one
time
ideal
tumor
archiv
center
provinci
nation
facil
addit
propos
guidelin
develop
assay
clinic
use
must
pass
stringent
clinic
laboratori
improv
amend
clia
standard
colleg
american
patholog
certif
diagnost
test
result
larg
cost
due
demonstr
improv
patient
mortal
outcom
replic
random
clinic
trial
cost
assay
import
paramet
experiment
design
minim
desir
translat
result
clinic
use
medic
cost
increas
current
healthcar
system
cure
sought
ill
gener
popul
age
increas
life
expect
result
money
put
toward
elderli
popul
care
medic
cost
costeffect
studi
may
perform
assay
determin
econom
util
consum
societi
wellb
new
biomark
may
undergo
costutil
studi
measur
sum
money
per
qualiti
adjust
life
year
qali
gain
ratio
cost
test
benefit
number
year
gain
taken
usd
per
qali
gain
consid
upperlimit
costeffect
addit
necess
develop
assay
low
cost
fda
guidelin
approv
must
met
fdaapprov
clinician
accept
employ
assay
